CSTL – Castle Biosciences Inc.
CSTL — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
4.94
Margin Of Safety %
11
Put/Call OI Ratio
0.21
EPS Next Q Diff
-0.23
EPS Last/This Y
-0.34
EPS This/Next Y
0.63
Price
23.55
Target Price
48.5
Analyst Recom
1.12
Performance Q
-41.31
Upside
-226.4%
Beta
1.18
Ticker: CSTL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | CSTL | 29.51 | 0.27 | 0.03 | 1795 |
| 2026-03-02 | CSTL | 27.99 | 0.27 | 0.04 | 1793 |
| 2026-03-03 | CSTL | 27.33 | 0.27 | 1.00 | 1806 |
| 2026-03-04 | CSTL | 28.2 | 0.27 | 0.00 | 1807 |
| 2026-03-05 | CSTL | 27.89 | 0.27 | 0.00 | 1807 |
| 2026-03-06 | CSTL | 27.09 | 0.27 | 1.57 | 1807 |
| 2026-03-09 | CSTL | 26.97 | 0.27 | 0.09 | 1807 |
| 2026-03-10 | CSTL | 26.58 | 0.26 | 0.00 | 1808 |
| 2026-03-11 | CSTL | 26.14 | 0.26 | 0.00 | 1825 |
| 2026-03-12 | CSTL | 25.29 | 0.26 | 0.00 | 1826 |
| 2026-03-13 | CSTL | 25.32 | 0.26 | 0.00 | 1826 |
| 2026-03-17 | CSTL | 25.89 | 0.26 | 0.00 | 1829 |
| 2026-03-18 | CSTL | 25.62 | 0.25 | 0.10 | 1828 |
| 2026-03-19 | CSTL | 25.69 | 0.25 | 0.00 | 1847 |
| 2026-03-20 | CSTL | 25.05 | 0.20 | 0.00 | 1783 |
| 2026-03-23 | CSTL | 25.71 | 0.25 | 999.99 | 1437 |
| 2026-03-24 | CSTL | 25.39 | 0.25 | 98.00 | 1438 |
| 2026-03-25 | CSTL | 25.24 | 0.21 | 0.00 | 1389 |
| 2026-03-26 | CSTL | 24.68 | 0.21 | 0.00 | 1385 |
| 2026-03-27 | CSTL | 23.56 | 0.21 | 20.00 | 1387 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | CSTL | 29.50 | 47.9 | -83.3 | -1.28 |
| 2026-03-02 | CSTL | 27.97 | 47.9 | -25.8 | -1.28 |
| 2026-03-03 | CSTL | 27.60 | 47.9 | -28.4 | -1.28 |
| 2026-03-04 | CSTL | 28.20 | 47.9 | -18.3 | -1.28 |
| 2026-03-05 | CSTL | 27.90 | 47.9 | -16.5 | -1.28 |
| 2026-03-06 | CSTL | 27.11 | 47.9 | -15.5 | -1.28 |
| 2026-03-09 | CSTL | 27.01 | 45.7 | -6.3 | -1.18 |
| 2026-03-10 | CSTL | 26.58 | 45.7 | -5.6 | -1.18 |
| 2026-03-11 | CSTL | 26.13 | 45.7 | -5.5 | -1.18 |
| 2026-03-12 | CSTL | 25.32 | 45.7 | -4.8 | -1.18 |
| 2026-03-13 | CSTL | 25.56 | 45.7 | -7.0 | -1.18 |
| 2026-03-17 | CSTL | 25.88 | 45.7 | -6.5 | -1.18 |
| 2026-03-18 | CSTL | 25.66 | 45.7 | -2.0 | -1.18 |
| 2026-03-19 | CSTL | 25.70 | 45.7 | -6.6 | -1.18 |
| 2026-03-20 | CSTL | 25.05 | 45.7 | -5.1 | -1.18 |
| 2026-03-23 | CSTL | 25.73 | 45.7 | -8.1 | -1.18 |
| 2026-03-24 | CSTL | 25.37 | 45.7 | -5.7 | -1.18 |
| 2026-03-25 | CSTL | 25.25 | 45.7 | -6.2 | -1.18 |
| 2026-03-26 | CSTL | 24.70 | 45.7 | -5.2 | -1.18 |
| 2026-03-27 | CSTL | 23.55 | 45.7 | -3.9 | -1.18 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | CSTL | -19.06 | -5.77 | 4.78 |
| 2026-03-02 | CSTL | -16.13 | -5.11 | 4.70 |
| 2026-03-03 | CSTL | -16.13 | -5.11 | 4.70 |
| 2026-03-04 | CSTL | -16.13 | -5.11 | 4.70 |
| 2026-03-05 | CSTL | -16.63 | -5.11 | 4.70 |
| 2026-03-06 | CSTL | -16.63 | -5.11 | 4.70 |
| 2026-03-09 | CSTL | -17.80 | -5.11 | 4.70 |
| 2026-03-10 | CSTL | -17.80 | -5.11 | 4.70 |
| 2026-03-11 | CSTL | -17.80 | -5.11 | 4.82 |
| 2026-03-12 | CSTL | -17.80 | -5.11 | 4.82 |
| 2026-03-13 | CSTL | -21.41 | -5.11 | 4.82 |
| 2026-03-17 | CSTL | -25.26 | -5.16 | 4.82 |
| 2026-03-18 | CSTL | -25.26 | -5.16 | 4.82 |
| 2026-03-19 | CSTL | -26.52 | -5.16 | 4.82 |
| 2026-03-20 | CSTL | -26.52 | -5.16 | 4.82 |
| 2026-03-23 | CSTL | -26.52 | -5.14 | 4.82 |
| 2026-03-24 | CSTL | -26.52 | -5.14 | 4.82 |
| 2026-03-25 | CSTL | -26.52 | -5.14 | 4.94 |
| 2026-03-26 | CSTL | -26.52 | -5.14 | 4.94 |
| 2026-03-27 | CSTL | -26.52 | -5.14 | 4.94 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.08
Avg. EPS Est. Current Quarter
-0.49
Avg. EPS Est. Next Quarter
-0.31
Insider Transactions
-26.52
Institutional Transactions
-5.14
Beta
1.18
Average Sales Estimate Current Quarter
79
Average Sales Estimate Next Quarter
85
Fair Value
26.07
Quality Score
52
Growth Score
58
Sentiment Score
40
Actual DrawDown %
70.2
Max Drawdown 5-Year %
-85
Target Price
48.5
P/E
Forward P/E
PEG
P/S
2.03
P/B
1.48
P/Free Cash Flow
24.69
EPS
-0.85
Average EPS Est. Cur. Y
-1.18
EPS Next Y. (Est.)
-0.54
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-7.02
Relative Volume
0.73
Return on Equity vs Sector %
-32.5
Return on Equity vs Industry %
-16.2
EPS 1 7Days Diff
EPS 1 30Days Diff
0.13
EBIT Estimation
-3.9
◆
CSTL
Healthcare
$23.53
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
25
Range 1M
0.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-41.5%
EPS NY
53.7%
52W%
30.9%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+48.9% upside
Upside
+48.9%
Quality
52
MoS
11%
Castle Biosciences, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 883
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
CSTL
Latest News
—
Caricamento notizie per CSTL…
stock quote shares CSTL – Castle Biosciences Inc. Stock Price stock today
news today CSTL – Castle Biosciences Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CSTL – Castle Biosciences Inc. yahoo finance google finance
stock history CSTL – Castle Biosciences Inc. invest stock market
stock prices CSTL premarket after hours
ticker CSTL fair value insiders trading